Skip to content
approvedCardiovascular

Nesiritide

Also known as: Natrecor, Recombinant Human BNP, rhBNP, Nesiritide Citrate

Nesiritide (Natrecor) is a recombinant form of human B-type natriuretic peptide (BNP) approved by the FDA in 2001 for intravenous treatment of acute decompensated heart failure with dyspnea at rest or with minimal activity. As a 32-amino acid peptide identical to endogenous human BNP, nesiritide produces vasodilation, natriuresis, and suppression of the RAAS. While it effectively reduces pulmonary capillary wedge pressure and improves symptoms, the landmark ASCEND-HF trial found it did not reduce mortality or rehospitalization, leading to a significant decline in clinical use.

4 cited references·5 researched benefits

Quick Answer

Nesiritide (Natrecor) is an FDA-approved recombinant form of human B-type natriuretic peptide used to treat acute decompensated heart failure. Administered intravenously, it rapidly reduces pulmonary pressures and improves breathing difficulty by promoting vasodilation, natriuresis, and RAAS suppression. Its half-life is approximately 18 minutes. While effective for symptom relief, the ASCEND-HF trial showed no mortality benefit, limiting its current clinical role.

Key Facts

Mechanism
Nesiritide is a 32-amino acid peptide identical to endogenous human BNP. It binds natriuretic peptide receptor A (NPR-A), activating particulate guanylate cyclase to increase intracellular cyclic GMP (cGMP). This produces: balanced arterial and venous vasodilation reducing both preload and afterload; natriuresis and diuresis through direct renal tubular effects and increased glomerular filtration; suppression of renin and aldosterone secretion; reduced sympathetic nervous system activation; and inhibition of endothelin-1 release. The net hemodynamic effect is reduced pulmonary capillary wedge pressure (PCWP), reduced right atrial pressure, and reduced systemic vascular resistance, with modest increases in cardiac output.
Research Status
approved
Half-Life
~18 minutes
Molecular Formula
C₁₄₃H₂₄₄N₅₀O₄₂S₄
Primary Use
Cardiovascular
Table of Contents

Benefits

  • Rapid reduction in pulmonary capillary wedge pressure (PCWP) — improves dyspnea within 15-30 minutes of infusionstrong
  • Balanced vasodilation — reduces both preload and afterload without direct inotropic stimulationstrong
  • Natriuresis and diuresis — promotes sodium and water excretionstrong
  • RAAS suppression — reduces aldosterone and renin levels during infusionstrong
  • No proarrhythmic effects — does not increase ventricular arrhythmia risk unlike dobutamine or milrinonemoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous bolus + infusion (FDA-approved)2 mcg/kg IV bolus over 60 seconds, followed by 0.01 mcg/kg/min continuous infusionContinuous infusion for up to 48 hoursBolus may be omitted if hypotension is a concern. Infusion rate can be increased by 0.005 mcg/kg/min every 3 hours (preceded by a 1 mcg/kg bolus) to a maximum of 0.03 mcg/kg/min. Do not initiate if systolic BP <90 mmHg.
Intravenous infusion without bolus0.005-0.01 mcg/kg/minContinuous infusionSome clinicians prefer to omit the bolus dose and start at the lower infusion rate to reduce hypotension risk, particularly in patients with borderline blood pressure or renal impairment.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hypotension (most common, occurs in ~11% of patients at approved doses)common
  • Headachecommon
  • Nauseacommon
  • Dizzinesscommon
  • Worsening renal function — dose-dependent decline in GFR, particularly in volume-depleted patientsserious
  • Symptomatic hypotension requiring discontinuation or vasopressor supportserious
  • Injection site reactions (IV site)common

Frequently Asked Questions

Why did nesiritide use decline after the ASCEND-HF trial?
The ASCEND-HF trial (2011, N=7,141) was a large randomized controlled trial that compared nesiritide to placebo in acute decompensated heart failure. While nesiritide produced a small, non-significant improvement in dyspnea at 6 and 24 hours, it did not reduce 30-day mortality or heart failure rehospitalization — the co-primary endpoints. It did cause more hypotension than placebo. This neutral result, combined with the high drug cost and the need for ICU-level monitoring, led most cardiologists to abandon routine nesiritide use in favor of nitroglycerin infusions and aggressive diuretic therapy, which are cheaper and equally effective for symptom relief.
Is nesiritide safe for the kidneys?
Renal safety was a major controversy for nesiritide. A 2005 meta-analysis by Sackner-Bernstein raised concerns about increased renal impairment and possibly increased mortality with nesiritide. However, the definitive ASCEND-HF trial subsequently found no significant difference in renal function between nesiritide and placebo groups. Current evidence suggests nesiritide does not worsen renal function at approved doses, but caution is warranted in volume-depleted patients or those with pre-existing severe renal impairment, as excessive hypotension can reduce renal perfusion.
How does nesiritide compare to nitroglycerin for acute heart failure?
The VMAC trial (2002) compared nesiritide to nitroglycerin in acute decompensated heart failure. Nesiritide produced a greater reduction in PCWP at 3 hours (5.8 mmHg vs 3.8 mmHg), but patient-reported dyspnea improvement was similar at 3 hours and not significantly different at 24 hours. Nitroglycerin is dramatically cheaper, has decades of clinical experience, can be titrated more rapidly (its half-life is only 1-3 minutes vs 18 minutes for nesiritide), and does not require a special preparation. These factors, combined with the ASCEND-HF neutral result, have made nitroglycerin the preferred vasodilator in most centers.
Is nesiritide still available and used?
Nesiritide (Natrecor) remains FDA-approved and commercially available, but its clinical use has declined dramatically since the ASCEND-HF trial in 2011. It is now used infrequently, primarily in patients who are intolerant of or unresponsive to standard vasodilators (nitroglycerin, nitroprusside) and diuretics. Some advanced heart failure centers use it in select cases, particularly in patients with severe right heart failure or cardiorenal syndrome where its natriuretic effects may be helpful. Annual US sales have fallen over 90% from peak usage.

References

  1. 1
    Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure (VMAC trial)(2002)PubMed ↗
  2. 2
    Effect of nesiritide in patients with acute decompensated heart failure (ASCEND-HF)(2011)PubMed ↗
  3. 3
    Renal effects of synthetic natriuretic peptide and nesiritide in heart failure: a systematic review(2005)PubMed ↗
  4. 4
    Nesiritide revisited: clinical pharmacology and updated clinical trial evidence(2012)PubMed ↗

Latest Research

Last updated: 2026-02-19